5α-Reductase inhibitors in prostate cancer

Endocrine-Related Cancer

Volumn 3, Issue 1, 1996, Pages 57-63

  Gormley, G J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; FINASTERIDE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR;

DRUG DESIGN; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW;

EID: 0029932785     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0030057     Document Type: Review

References (35)

1. Andersson S & Russell DW 1990 Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proceedings of the National Academy of Sciences of the USA 87 3640-3644.
2. Andersson S, Bishop RW & Russell DW 1989 Expression cloning and regulation of steroid 5α-reductase, an enzyme essential for male sexual differentiation. Journal of Biological Chemistry 264 16249-16255.
3. Andriole G, Lieber M, Smith J, Soloway M, Schroeder F, Kadmon D, DeKernion J, Rajfer J, Boake R, Crawford D, Ramsey E, Perreault J, Trachtenberg J, Fradet Y, Block N, Middleton R, Ng J, Ferguson D & Gormley G 1995 Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 45 491-497.
4. Bologna M, Muzi P, Biordi L, Festuccia C & Vicentini C 1992 Antiandrogens and 5α-reductase inhibition of the proliferation rate in PC3 and DU145 human prostatic cancer cell lines. Current Therapeutic Research 51 799-813.
5. Bologna M, Muzi P, Biordi L, Festuccia C & Vicentini C 1995 Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology 45 282-290.
6. Boring CC, Squires TS & Tong T 1992 Cancer statistics. CA-A Cancer Journal for Clinicians 42 19-38.
7. Brooks JR, Berman C, Hguyen H, Prahalada S, Primka RL, Rasmusson GH & Slater EE 1991 Effect of castration, DES, flutamide, and the 5α-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327. Prostate 18 215-227.
8. Diani AR, Mullholland MJ, Shull KL, Kubicek MF, Johnson GA, Schostarez HJ, Brunden MN & Buhl AE 1982 Hair growth effects of oral administration of finasteride, a steroid 5α-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. Journal of Clinical Endocrinology and Metabolism 74 345-350.
9. Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA, Brawley OW & Ford LG 1995 Design of the Prostate Cancer Prevention Trial (PCPT). Controlled Clinical Trials 16 150-163.
10. Fleshner NE & Trachtenberg J 1993 Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: Early results. European Urology 24 (Suppl 2) 106-112.
11. Fleshner NE, Fair WR & Trachtenberg J 1995 Further experience with sequential androgen blockade. Journal of Urology 153 Abstract 882.
12. Fruzzetti F, de Lorenzo D, Parrini D & Ricci C 1994 Effects of finasteride, a 5α-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. Journal of Clinical Endocrinology and Metabolism 79 831-835.
13. Geller J & Sionit L 1992 Castration-like effects on the human prostate of a 5α-reductase inhibitor, finasteride. Journal of Cellular Biochemistry 16H (Suppl) 109-112.
14. George FW, Russell DW & Wilson JD 1991 Feed forward control of prostate growth: Dihydrotestosterone induces expression of its own biosynthetic enzyme steroid 5αreductase. Proceedings of the National Academy of Sciences of the USA 88 8044-8047.
15. Gormley GJ 1992 Chemoprevention strategies for prostate cancer. The role of 5α-reductase inhibitors. Workshop Conference on Chemoprevention of Premalignant and Early Malignant Lesions of the Prostate. Journal of Cellular Biochemistry 16H (Suppl) 113-117.
16. Gormley GJ, Stoner E, Rittmaster RS, Gregg H, Thompson DL, Lasseter KG, Vlasses PH & Stein EA 1990 Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgens in male volunteers. Journal of Clinical Endocrinology and Metabolism 70 1136-1141.
17. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B & Ng J 1992 The effect of finasteride in men with benign prostatic hyperplasia. New England Journal of Medicine 327 1185-1191.
18. Guess HA, Gormley GJ, Stoner E & Oesterling JE 1996 The effect of finasteride on prostate specific antigen: review of the available data. Journal of Urology 155 3-9.
19. Henschel T, Kuhn R, Schafhauser W & Schrott KM 1994 XLVI Kongreb der Deutschen Gesellschaft für Urologic e.v. Abstract S34. Stuttgart: Springer-Verlag.
20. Higgins C & Hodges CV 1941 Studies on prostatic cancer; effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of prostate. Cancer Research 1 293-297.
21. Imperato-McGinley J, Guerrero L, Gautier T & Peterson RE 1974 Steroid 5α-reductase deficiency in man: An inherited form of malepseudohermaphroditism. Science 186 1213-1215.
22. Jenkins EP, Hsieh C-L, Milatovich A, Normington K, Berman DM, Francke U & Russell DW 1991 Characterization and chromosomal mapping of a human steroid 5α-reductase gene and pseudogene and mapping of the mouse homologue. Genomics 11 1102-1112.
23. Kaufman KD, DeVillez R, Roberts J, Fiedler V, Olsen E, Imperato-McGinley J, Whiting D, Shupack J, Stough E, Rietschel R, Savin R, Bergfeld W, Muller S, Millikan L, Canfield D, Jacobsen C, Binkowitz B & Gormley GJ 1994 A 12 month pilot clinical study of the effects of finasteride on men with male pattern baldness. 55th Annual Meeting of the Society of Investigative Dermatology, Abstract 550.
24. Lamb JC, Levy MA, Johnson RK & Isaacs JT 1992 Response of rat and human prostatic cancers to the novel 5α-reductase inhibitor SK&F 105657. Prostate 20 15-34.
25. Moghetti P, Castello R, Magnani CM, Tosi F, Negri C, Armanim D, Bellotti G & Muggeo M 1994 Clinical and hormonal effects of the 5α-reductase inhibitor finasteride in idiopathic hirsutism. Journal of Clinical Endocrinology and Metabolism 79 1115-1121.
26. Moore RJ & Wilson JD 1976 Steroid 5α-reductase in cultured human fibroblasts: Biochemical and genetic evidence for two distinct enzyme activities. Journal of Biological Chemistry 251 5895-5900.
27. Presti JC, Fair WR, Andriole G, Sogani P, Seidmon EJ, Ferguson D, Ng J & Gormley GJ 1992 Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on Stage D prostate cancer. Journal of Urology 148 1201-1204.
28. Sakr WA, Haas GP, Cassin BF, Pontes JE & Crissman JD 1993 The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. Journal of Urology 150 379-385.
29. Stoner E, Round E, Ferguson D, Gormley GJ & the Finasteride Study Group 1994 Clinical experience of the detection of prostate cancer in patients with benign prostatic hyperplasia treated with finasteride. Journal of Urology 151 1296-1300.
30. The Finasteride Study Group 1993 Finasteride (Mk-906) in the treatment of benign prostatic hyperplasia. Prostate 22 291-299.
31. Thigpen AE, Davis DL, Milatovich A, Mendonca BB, Imperato-McGinley J, Griffin JE, Francke U, Wilson JD & Russell DW 1992a Molecular genetics of steroid 5αreductase 2 deficiency. Journal of Clinical Investigation 90 799-809.
32. Thigpen AE, Davis DL, Gautier T, Imperato-McGinley J & Russell DW 1992b The molecular basis of steroid 5αreductase deficiency in a large Dominican kindred. New England Journal of Medicine 327 1216-1219.
33. Tsukamoto S, Akaza H, Imada S, Koiso K, Shirai T, Ideyama Y & Kudo M 1995 Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. Journal of the National Cancer Institute 87 842-843.
34. Walsh PC, Madden JD, Harrod MJ, Goldstein JL, MacDonald PC & Wilson JD 1974 Familial incomplete male pseudohermaphroditism, Type 2 decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. New England Journal of Medicine 291 944-949.
35. Wong IL, Morris RS, Chang L, Spahn M, Stanczyk FZ & Lobo RA 1995 A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. Journal of Clinical Endocrinology and Metabolism 80 233-238.